Online citations, reference lists, and bibliographies.

A Comparison Of Histamine Receptor Antagonists Versus Proton Pump Inhibitor Gastrointestinal Ulcer Prophylaxis In Kidney Transplant Recipients

Ginger E Rouse, Karen L. Hardinger, Demetra S. Tsapepas, Eric M Tichy
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Introduction: There are several different agents that can be used for gastrointestinal (GI) ulcer prophylaxis in posttransplant recipients, such as histamine-2 receptor antagonists (H2RA) or proton pump inhibitors (PPIs). Research Question: This study was conducted to compare the incidence of adverse kidney events in transplant recipients who received prophylaxis with H2RAs or PPIs. Design: This retrospective study included all kidney transplant recipients from 3 transplant centers who were transplanted in 2009 through 2011. The primary objective was to compare the incidence of adverse events posttransplant, defined as the incidence of pneumonia, Clostridium difficile, hip fractures, GI bleeding, cytomegalovirus, organ rejection, and bacteremia. Results: A total of 211 patients were included in the study; of which 35 were included in the PPI group and 176 were included in the H2RA group. There were no significant differences between groups in regard to incidence of GI bleeding events or other adverse events. Discussion: These findings suggest there is a low incidence of GI ulcers and upper GI bleeding events after kidney transplantation with the use of H2RAs or PPIs. Additionally, there are similar rates of adverse events when comparing H2RAs versus PPIs for GI ulcer prophylaxis.
This paper references
Proton-pump inhibitor use is associated with low serum magnesium concentrations.
John I. Danziger (2013)
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
Sinem Ezgi Gulmez (2007)
of Health and Human Services, FDA Drug Safety Communication
US Departmen (2016)
IMS Health ISNP , Top 20 Therapeutic Classes 2012 . Dispensed prescriptions , data from 2012
RJ Nardino
ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998.
A long - term comparison of tacrolimus ( FK 506 ) and cyclosporine in kidney
F Vincenti
The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.
Sieglinde Kofler (2011)
Concomitant Proton Pump Inhibitors With Mycophenolate Mofetil and the Risk of Rejection in Kidney Transplant Recipients
John P. Knorr (2014)
ASHP therapeutic guidelines on stress ulcer prophylaxis
T. A. Armstrong (1999)
Top 20 Therapeutic Classes 2012
IMS Health ISNP (2016)
Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers.
Korbinian Rupprecht (2009)
Overuse of Acid Suppression Therapy in Hospitalized Patients
Ruchi Gupta (2010)
J. Pirsch (1997)
Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study.
Sieglinde Kofler (2009)
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.
F. Vincenti (2002)
Acid Suppressive Therapy Use on an Inpatient Internal Medicine Service
Co Q. D. Pham (2006)
Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.
Deborah J Cook (1994)
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit.
Catherine E. Murphy (2008)
Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group.
D. Cook (1999)
KDIGO clinical practice guideline for the care of kidney transplant recipients.
Supporting Tables (2009)
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies
S. Dial (2004)
Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients
Christine E Staatz (2007)
Overuse of acid-suppressive therapy in hospitalized patients
R. Nardino (2000)
Management of Patients With Ulcer Bleeding
Loren Laine (2012)
Contemporary strategies for the prevention of stress-related mucosal bleeding.
R. Martindale (2005)
Proton pump inhibitor drugs ( PPI ) : drug safety communication — low magnesium levels can be associated with long - term use . Web site
F Vincenti
Prevention of stress ulceration: Current trends in critical care
Ryan J. Daley (2004)
Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.
Sieglinde Kofler (2009)
Risk factors for gastrointestinal bleeding in critically ill patients
Deborah J Cook (1994)
When should stress ulcer prophylaxis be used in the ICU?
J. Quenot (2009)
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation
F Vincenti (2002)
A comparison of tacrolimus ( FK 506 ) and cyclosporine for immunosuppression after cadaveric renal transplantation . FK 506 Kidney Transplant Group
CE Staatz (1997)
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
R. Laheij (2004)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar